Public Sector Pension Investment Board (PSP Investments)’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.67M Buy
851,413
+27,725
+3% +$438K 0.02% 692
2025
Q4
$15M Sell
823,688
-107,112
-12% -$1.81M 0.05% 298
2025
Q3
$13.6M Buy
930,800
+116,867
+14% +$2M 0.05% 330
2025
Q2
$14.8M Buy
813,933
+64,231
+9% +$1.31M 0.06% 239
2025
Q1
$14.9M Buy
749,702
+160,762
+27% +$2.78M 0.06% 230
2024
Q4
$10.1M Buy
588,940
+94,440
+19% +$1.78M 0.04% 329
2024
Q3
$9.89M Buy
+494,500
New +$7.69M 0.05% 216

Other funds holding ADMA

Public Sector Pension Investment Board (PSP Investments)'s ADMA Position: Q1 2026 in Review

Public Sector Pension Investment Board (PSP Investments) increased its ADMA Biologics (ADMA) stake by 3.4% in Q1 2026, buying an estimated $438K and bringing the position to 851,413 shares worth $7.67M. The position accounts for 0.02% of the portfolio, ranked #692.

Public Sector Pension Investment Board (PSP Investments) first reported a position in ADMA in Q3 2024 and has held it in 7 quarters since. The position peaked at $15M in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Public Sector Pension Investment Board (PSP Investments) held 851,413 shares of ADMA Biologics worth $7.67M as of Q1 2026.
  • Public Sector Pension Investment Board (PSP Investments) bought 27,725 ADMA Biologics shares in Q1 2026, an estimated $438K.
  • ADMA Biologics made up 0.02% of Public Sector Pension Investment Board (PSP Investments)'s portfolio in Q1 2026, its #692 holding.
  • Public Sector Pension Investment Board (PSP Investments) first reported a position in ADMA Biologics in Q3 2024 and has held it in 7 quarters since.
  • Public Sector Pension Investment Board (PSP Investments)'s ADMA Biologics position peaked at $15M in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Public Sector Pension Investment Board (PSP Investments)'s 13F filing for Q1 2026, filed 13 May 2026.